COMPANY PROFILE // THE 014 REPORT
Ironwood Pharmaceuticals Inc.
IRWD (Nasdaq)
Assembled from 4 government sources in 3.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-16: a pattern of leadership change.
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-07-10 (last 24 months).
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-06-03 and 1 more time (last 24 months).
- AmberNT 10-K filed on 2025-03-03: notice that a periodic report would be late.
- AmberLEI 549300PC8MR6QHH6P296 registration status is LAPSED (last update 2025-01-04): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
IRONWOOD PHARMACEUTICALS INC is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Boston, MA; listed as IRWD (Nasdaq).[source] It reported revenue of $296.2 million for the fiscal year ended 2025-12-31.[source] It has filed 71 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., ARMISTICE CAPITAL, LLC, Sarissa Capital Management LP (as of 2026-06-30).[source] Seraphix flags 5 items from these records: 8-K Item 4.01 filed; 8-K Item 3.01 filed; 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-16.[source]
- red0
- amber5
- info1
- BlackRock, Inc.$74.9M
- ARMISTICE CAPITAL, LLC$58.7M
- Sarissa Capital Management LP$38.7M
- STATE STREET CORP$37.1M
- BANK OF AMERICA CORP /DE/$36.6M
- RENAISSANCE TECHNOLOGIES LLC$33.7M
- VANGUARD CAPITAL MANAGEMENT LLC$27.8M
- AQR CAPITAL MANAGEMENT LLC$27.2M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- Gaskins Tammi L · Chief Commercial Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- John Minardo · Chief Legal Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- MCCOURT Thomas A · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Martini Gregory S. · Chief Financial Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Shetzline Michael · SVP, CMO, Head-Res&Drug (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Silver Ronald · Principal Accounting Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Currie Mark G · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- DENNER ALEXANDER J · Director · latest Form 4 2026-03-17 · filing · LinkedIn search
- Dreyfus Andrew · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Duane Jon R · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Kessler Marla L · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- McHugh Julie · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Wilmer Cutler Pickering Hale and Dorr LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-11-05
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001446847 | source |
| LEI | 549300PC8MR6QHH6P296 | source |
| EIN | 04-3404176 | source |
| NY DOS ID | 4244217 | record |
| Connecticut business ID | 1286172 | record |
| Business address (SEC) | 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110 | source |
Does not exist in the records we hold: UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2025-01-04 · in -685 days · LEI next renewal (549300PC8MR6QHH6P296)
- 2027-03-16 · in 116 days · Next 10-K due (period ended 2026-12-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- PLIANT THERAPEUTICS, INC. · MCCOURT Thomas A
- Alto Neuroscience, Inc. · Dreyfus Andrew
- Lantheus Holdings, Inc. · McHugh Julie
- MoonLake Immunotherapeutics · Moukheibir Catherine
- INOVIO PHARMACEUTICALS, INC. · Shepard Jay
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing 144 · SEC EDGAR
- 2026-11-05 filing S-8 · SEC EDGAR
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-16 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-09-23 filing 144 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-07 filing 144 · SEC EDGAR
- 2026-06-18 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-06-16 filing 144 · SEC EDGAR
- 2026-06-15 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-21 officer change 8-K/A items 5.02 · SEC EDGAR
- 2026-05-13 officer change 8-K items 5.02 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
- 2026-03-19 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-03-11 filing 8-K items 8.01 · SEC EDGAR
- 2026-02-26 filing Annual report (10-K) · SEC EDGAR
- 2026-02-25 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-25 insider First Form 3/4/5 on record for Shetzline Michael (SVP, CMO, Head-Res&Drug) · SEC Forms 3/4/5
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-01-05 filing 144 · SEC EDGAR
132 earlier entries
- 2026-01-02 filing 8-K items 2.02,9.01
- 2025-12-23 filing 8-K items 1.01,8.01,9.01
- 2025-11-26 filing 8-K items 8.01
- 2025-11-14 filing 144
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-10-10 officer change 8-K items 5.02
- 2025-09-03 filing 8-K items 8.01
- 2025-08-13 insider First Form 3/4/5 on record for John Minardo (Chief Legal Officer)
- 2025-08-13 insider First Form 3/4/5 on record for Martini Gregory S. (Chief Financial Officer)
- 2025-08-13 insider First Form 3/4/5 on record for Silver Ronald (Principal Accounting Officer)
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-08 filing 144
- 2025-08-08 filing 144
- 2025-08-08 filing 144
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-07-10 filing 8-K items 4.01,9.01
- 2025-06-12 filing 8-K items 5.07
- 2025-06-12 insider First Form 3/4/5 on record for Currie Mark G (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Dreyfus Andrew (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Duane Jon R (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Kessler Marla L (Director)
- 2025-06-12 insider First Form 3/4/5 on record for McHugh Julie (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Moukheibir Catherine (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Shepard Jay (Director)
- 2025-06-03 filing 8-K items 3.01
- 2025-05-20 insider First Form 3/4/5 on record for Gaskins Tammi L (Chief Commercial Officer)
- 2025-05-20 insider First Form 3/4/5 on record for MCCOURT Thomas A (Chief Executive Officer)
- 2025-05-16 filing 144
- 2025-05-16 filing 144
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-07 filing 8-K items 2.02,9.01
- 2025-04-28 filing ARS
- 2025-04-28 filing DEFA14A
- 2025-04-28 filing Proxy statement
- 2025-04-25 filing 8-K items 2.02,9.01
- 2025-04-14 filing 8-K items 8.01,9.01
- 2025-04-04 insider First Form 3/4/5 on record for DENNER ALEXANDER J (Director)
- 2025-03-31 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 3.01,7.01,9.01
- 2025-03-03 filing NT 10-K
- 2025-02-27 filing 8-K items 2.02,9.01
- 2025-02-07 filing 144
- 2025-02-07 filing 144
- 2025-02-07 filing 144
- 2025-02-07 filing 144
- 2025-01-29 officer change 8-K items 2.05,5.02
- 2024-12-27 filing 144
- 2024-12-05 officer change 8-K items 5.02
- 2024-11-15 filing 144
- 2024-11-15 filing 144
- 2024-11-12 officer change 8-K items 5.02
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-09-30 filing 8-K items 1.01,2.03,8.01,9.01
- 2024-08-09 filing 144
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-06-21 filing 8-K items 5.07
- 2024-06-20 officer change 8-K items 5.02,8.01
- 2024-06-10 filing 144
- 2024-06-07 filing 144
- 2024-06-06 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-25 filing ARS
- 2024-04-25 filing DEFA14A
- 2024-04-25 filing Proxy statement
- 2024-02-16 filing Annual report (10-K)
- 2024-02-15 filing 8-K items 2.02,9.01
- 2024-02-09 filing 144
- 2024-02-09 filing 144
- 2024-02-09 filing 144
- 2024-02-09 filing 144
- 2024-01-08 filing 8-K items 2.02,9.01
- 2023-12-14 filing 144
- 2023-12-06 filing UPLOAD
- 2023-11-30 filing CORRESP
- 2023-11-17 filing 144
- 2023-11-15 filing UPLOAD
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-11-09 filing S-8
- 2023-11-09 filing S-3ASR
- 2023-11-09 filing 8-K items 2.02,9.01
- 2023-09-11 filing 8-K/A items 9.01
- 2023-08-11 filing 144
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-08 filing 8-K items 2.02,9.01
- 2023-08-01 filing 144
- 2023-07-07 filing SC 13D
- 2023-06-30 filing 8-K items 2.01,2.03,8.01,9.01
- 2023-06-29 filing SC TO-T/A
- 2023-06-26 filing SC TO-T/A
- 2023-06-22 officer change 8-K items 5.02,5.07,9.01
- 2023-06-20 filing SC TO-T/A
- 2023-06-16 filing SC TO-T/A
- 2023-06-07 filing 144
- 2023-05-31 filing SC TO-T
- 2023-05-30 filing 144
- 2023-05-23 filing SC TO-C
- 2023-05-22 filing SC TO-C
- 2023-05-22 filing SC TO-C
- 2023-05-22 filing 8-K items 1.01,2.03,8.01,9.01
- 2023-05-19 filing 144
- 2023-05-19 filing 144
- 2023-05-19 filing 144
- 2023-05-08 filing 144
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-04-27 filing ARS
- 2023-04-27 filing DEFA14A
- 2023-04-27 filing Proxy statement
- 2023-04-11 officer change 8-K items 5.02
- 2023-02-16 filing Annual report (10-K)
- 2023-02-16 filing 8-K items 2.02,9.01
- 2023-01-09 filing 8-K items 2.02,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-08-04 filing Quarterly report (10-Q)
- 2022-08-04 filing 8-K items 2.02,9.01
- 2022-06-03 filing 8-K items 5.07
- 2022-05-05 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-04-21 filing DEFA14A
- 2022-04-21 filing Proxy statement
- 2022-02-18 filing Annual report (10-K)
- 2022-02-17 filing 8-K items 2.02,9.01
- 2022-01-10 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-05 (within 30 days) S-8 filed (FORM S-8)
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-16 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-09-29 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-06 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:IRWD The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
5 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1446847 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | IRWD / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300PC8MR6QHH6P296 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300PC8MR6QHH6P296) | GLEIF |
| EIN | 043404176 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001446847 | SEC EDGAR / IRS |
| CUSIP | 46333X108 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001446847 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $296,151,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 00:42 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $24,017,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:42 UTC | Report an error |
| Total assets (at 2025-12-31) | $396,901,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:42 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$261,835,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:42 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $215,456,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:42 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
| State of incorporation | DE | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
| Business address | 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-21 00:42 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $127,044,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:42 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $34,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 00:42 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $13,122,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:42 UTC | Report an error |
| Form D total offering amount (D filed 2016-10-11) | $150,000,000 | 2016-10-11 | D | as filed | 2026-11-21 00:42 UTC | Report an error |
| Form D total amount sold (D filed 2016-10-11) | $150,000,000 | 2016-10-11 | D | as filed | 2026-11-21 00:42 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2016-10-11 | D | as filed | 2026-11-21 00:42 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2016-10-11 | D | as filed | 2026-11-21 00:42 UTC | Report an error |
| Form D date of first sale | 2016-09-23 | 2016-10-11 | D | as filed | 2026-11-21 00:42 UTC | Report an error |
| Plan (pension, plan no. 001) | IRONWOOD PHARMACEUTICALS, INC. 401(K) SAVINGS PLAN: 347 participants, assets $73,205,148 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 00:42 UTC | Report an error |
| Plan (welfare, plan no. 501) | IRONWOOD PHARMACEUTICALS, INC. HEALTH AND WELFARE PLAN: 89 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 00:42 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123319
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $133,040,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123319 | 2026-11-21 00:42 UTC | Report an error |
| Net income (loss) | $59,838,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123319 | 2026-11-21 00:42 UTC | Report an error |
| Interest expense | $6,198,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123319 | 2026-11-21 00:42 UTC | Report an error |
| Cash and cash equivalents | $86,376,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123319 | 2026-11-21 00:42 UTC | Report an error |
| Contract liabilities, current | $1,262,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123319 | 2026-11-21 00:42 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $201,500,000 | at 2025-09-30 | 10-Q | 2025-11-10 | 0001104659-25-108795 | 2026-11-21 00:42 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-05 Filing S-8 filed (FORM S-8)
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-16 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-09-29 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-06 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-18 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-15 Filing 8-K filed: Item 8.01 other event
- 2026-05-21 Filing 8-K/A filed: Item 5.02 officer or director change
- 2026-05-13 Filing 8-K filed: Item 5.02 officer or director change
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-28 Filing ARS filed
- 2026-04-28 Filing DEFA14A filed
- 2026-04-28 Filing DEF 14A filed
- 2026-03-11 Filing 8-K filed: Item 8.01 other event
- 2026-02-26 Filing 10-K filed
- 2026-02-25 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-02 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-12-23 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2025-11-26 Filing 8-K filed: Item 8.01 other event
- 2025-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-10 Filing 10-Q filed
4 earlier entries
- 2025-10-10 Filing 8-K filed: Item 5.02 officer or director change
- 2025-09-03 Filing 8-K filed: Item 8.01 other event
- 2002-08-01 Record plan effective date: IRONWOOD PHARMACEUTICALS, INC. HEALTH AND WELFARE PLAN
- 1999-01-01 Record plan effective date: IRONWOOD PHARMACEUTICALS, INC. 401(K) SAVINGS PLAN
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to the 8-K · retrieved 2026-11-21 00:42 UTC - 2026-11-05 8-K Item 2.02, of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-21 00:42 UTC - 2026-10-16 8-K Item 5.02, Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Ironwood Pharmaceuticals, Inc. (the “Company”) today announced that, on October 12, 2026, the Board of Directors (the “Board”) appointed Tammi Gaskins, the Company’s Senior Vice President, Chief Commercial Officer, as Chief Executive Officer, effective January 1, 2027 (the “Transition Date”). The Board increased the size of the Board from eight to nine directors and elected Ms. Gaskins as a director, in each case, effective as of the Transition Date. Biographical information for Ms. Gaskins is available on page 22 in the Company’s proxy statement filed with the Securities and Exchange Commission (the… the 8-K · retrieved 2026-11-21 00:42 UTC - 2026-08-06 8-K Item 2.02, Results of Operations and Financial Condition
On August 6, 2026, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to the 8-K · retrieved 2026-11-21 00:42 UTC - 2026-08-06 8-K Item 2.02, of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-21 00:42 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $74,889,826 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 2 | ARMISTICE CAPITAL, LLC | $58,653,720 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 3 | Sarissa Capital Management LP | $38,684,153 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 4 | STATE STREET CORP | $37,088,420 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 5 | BANK OF AMERICA CORP /DE/ | $36,558,810 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 6 | RENAISSANCE TECHNOLOGIES LLC | $33,651,481 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $27,821,819 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 8 | AQR CAPITAL MANAGEMENT LLC | $27,221,528 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | $23,211,225 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $20,345,036 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:42 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- IRONWOOD PHARMACEUTICALS, INC. · LEI 549300PC8MR6QHH6P296 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
5 state and city records carry this company's exact name, from 4 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIRONWOOD PHARMACEUTICALS · exact name match to 'IRONWOOD PHARMACEUTICALS INC' (no other entity shares the name) · sx:elic:ctcred:2536323 Compare
- possible matchIRONWOOD PHARMACEUTICALS INC · exact legal name · sx:elic:ctcred:1369902 Compare
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIRONWOOD PHARMACEUTICALS, INC. · exact legal name · sx:ctsos:1286172 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIronwood Pharmaceuticals, Inc. · exact legal name · sx:ctgov:h47a222bbe9a62058 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchIRONWOOD PHARMACEUTICALS, INC. · exact legal name · sx:nydos:4244217 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1446847.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001446847. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.